MGMA: Physician Practices Oppose Mandatory Medicare APMs

March 1, 2018
Medical group practices overwhelmingly desire flexibility and financial incentives when it comes to moving to Medicare alternative payment models (APMs) according to a new MGMA Stat poll.

Medical group practices overwhelmingly desire flexibility and financial incentives when it comes to moving to Medicare alternative payment models (APMs) according to a new MGMA Stat poll.

The poll, from the Colorado-based Medical Group Management Association (MGMA), garnered nearly 1,200 responses from its members. Seventy-two percent said that the government should not mandate participation in Medicare alternative payment models; 14 percent said they should mandate participation; and 14 percent they were unsure.

“Despite support for APMs, a large majority of physician practices oppose government mandated participation, citing lack of evidence, diversity among medical practices, and the negative impact on practice innovation,” said Anders Gilberg, MGMA senior vice president of government affairs.

MGMA has long championed voluntary APM opportunities for physician group practices of different types, sizes and specialties and continues to urge CMS to eliminate barriers to physician participation in payment models that support high-quality, cost-effective patient care. 

It remains to be seen just how ready physician practices are to transition to these types of care delivery models, though there have been positive signs of late. In one recent survey, medical groups and health systems that are members of AMGA (the American Medical Group Association) said they expect that nearly 60 percent of their revenues from Medicare will be from risk-based products by 2019.

Another report from the Health Care Payment Learning and Action Network (LAN) revealed that nearly one-third (29 percent) of total U.S. healthcare payments were tied to APMs such as shared savings/risk arrangements, bundled payments, or population-based reimbursements, in 2016, a six percentage point increase from 2015.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1